# Treatment of metabolic acidosis in hemodialysis patients with reduced daily pill burden



Nicoline M.H. Veldhuijzen, K.G.F. Gerritsen, W.H. Boer, A.C. Abrahams Department of Nephrology and Hypertension, UMC Utrecht, The Netherlands

# Background

- Metabolic acidosis in hemodialysis (HD) patients is associated with increased mortality
- Target predialysis plasma bicarbonate concentration ([HCO<sub>3</sub>-]<sub>p</sub>) is 20-22mmol/L
- Guidelines recommend treatment with oral NaHCO<sub>3</sub> and/or individualized dialysate bicarbonate concentration ([HCO<sub>3</sub>-]<sub>d</sub>)


# Aim of study

• Evaluate efficacy and safety of discontinuation of oral NaHCO<sub>3</sub> and upward adjustment of [HCO<sub>3</sub>-]<sub>d</sub>

#### Methods

- Study population: all HD patients treated with oral NaHCO<sub>3</sub> (n=19)
- Intervention:
  - 1) discontinuation of oral NaHCO<sub>3</sub> and increasing [HCO<sub>3</sub>-]<sub>d</sub> by 1-3mmol/L (depending on oral NaHCO<sub>3</sub> dose)
  - 2) weekly titration of  $[HCO_3^-]_d$  targeting predialysis  $[HCO_3^-]_p$  of 20-22mmol/L
- Outcome: pre- and postdialysis acid-base status, electrolytes and weight before and two months after implementation of the protocol

#### **Results**








Figure 2




Figure 3

Table 1	Before	After	n
			p
Dialysate bicarbonate (mmol/L)	34[34-35]	35[34-38]	0.02
Target predialysis plasma bicarbonate 20-22 mmol/L	7	8	1.00
Predialysis plasma bicarbonate ≥20 mmol/L	17	15	0.66
Postdialysis plasma bicarbonate >29 mmol/L	1	2	1.00
Postdialysis			
рН	7.47[7.43-7.50]	7.49[7.45-7.50]	0.36
pCO2 (mmHg)	41[35-43]	38[37-42]	0.88
Total calcium (mmol/L)	2.59[2.48-2.62]	2.64 [2.52-2.74]	0.12
Ionized calcium (mmol/L)	1.28[1.22-1.30]	1.25[1.19-1.31]	0.17
Sodium (mmol/L)	139[136-140]	139[138-141]	0.34
Potassium (mmol/L)	3.5[3.2-3.6]	3.5[3.3-3.8]	0.35
Interdialytic weight gain (kg)	1.9[1.3-3.5]	2.2[1.6-3.3]	0.73
Dosage sodium bicarbonate tablets (mg)	1500[1000-3000]	0[0-0]	< 0.0001

Values are median [interquartile range] or number

### Efficacy:

- [HCO<sub>3</sub>-]<sub>d</sub> is positively correlated with postdialysis [HCO<sub>3</sub>-]<sub>p</sub> (figure 1)
- Median predialysis  $[HCO_3]_p$  was 22.3 [21.0-24.3] mmol/L with old and 21.7 [20.1-23.0] mmol/L with new protocol (figure 2)
- Target predialysis and predialysis plasma bicarbonate was equally achieved (table 1)

#### Safety:

- Median postdialysis [HCO<sub>3</sub>-]<sub>p</sub> was 25.7 [25.1-26.7] mmol/L with old and 26 [23.9-28.2] mmol/L with new protocol (figure 3)
- Postdialysis  $[HCO_3^-]_p > 29 \text{ mmol/L was observed equally frequent (table 1)}$
- No differences in postdialysis electrolyte concentrations with the new protocol (table 1)


#### Patient friendliness/Cost efficacy:

- Daily tablet load reduction per patient: 3 [2-6]
- Increasing [HCO<sub>3</sub>-]<sub>d</sub> does not influence HD cost

# **Conclusion and perspectives**

- Individualized [HCO<sub>3</sub>-]<sub>d</sub> seems an adequate, safe, cost effective and patient friendly alternative treatment for metabolic acidosis compared to oral NaHCO<sub>3</sub>
- Randomized long-term studies with clinical endpoints are warranted for proper safety assessment









N.M.H.Veldhuijzen@umcutrecht.nl